I like to see that CKD is there.. RVX should really pursue that CKD route seriously since it is very expensive disease, i.e., dialysis, and a huge issue with transplant, i.e., ethical issues, waiting list, organ shortage, trip to overseas to get transplants, etc. Any jurisdictions in Canada or any funding bodies would be happy to fund this drug for kidney disease (given that it'd delay progression of CKD and prevent ESRD, transplant, etc.)

DM mentioned that there's not been a new kidney drug over a decade (according to expert).

I can understand that CVD has a big population and pay-off might be bigger, if successful... (Wasn't effect statistically significant in a subset of renal patients in BOM1 trial? vs. total study population, which was not..? Corrrect me if i'm wrong)  Apabetalone may have a bigger impact on the CKD and health care in that regards.